A missense cystic fibrosis transmembrane conductance regulator mutation with variable phenotype

被引:19
|
作者
Kerem, E
NissimRafinia, M
Argaman, Z
Augarten, A
Bentur, L
Klar, A
Yahav, Y
Szeinberg, A
Hiba, O
Branski, D
Corey, M
Kerem, B
机构
[1] HEBREW UNIV JERUSALEM, DEPT GENET, IL-91904 JERUSALEM, ISRAEL
[2] CHAIM SHEBA MED CTR, DEPT PAEDIAT, CF CLIN, IL-52621 TEL HASHOMER, ISRAEL
[3] RAMBAM MED CTR, DEPT PAEDIAT, CF CLIN, HAIFA, ISRAEL
[4] BIKUR CHOLIM HOSP, DEPT PAEDIAT, JERUSALEM, ISRAEL
[5] HOSP SICK CHILDREN, RES INST, TORONTO, ON M5G 1X8, CANADA
关键词
cystic fibrosis; genotype-phenotype correlation; genetics; pancreatic function; pulmonary function; CFTR mutation;
D O I
10.1542/peds.100.3.e5
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Objective. Cystic fibrosis (CF) has variable clinical presentation. Disease severity is partially associated with the type of mutation. The aim of this study was to report genotype-phenotype analysis of the G85E mutation. Patients. The phenotype of 12 patients (8 were from the same extended family, and 5 of them were siblings from 2 families) carrying at least one copy of the G85E mutation was evaluated and compared with the phenotype of 40 patients carrying the two severe mutations, W1282X and/or Delta F508 (group 1), and with 20 patients carrying the splicing mutation, 3849+10kb C->T, which was found to be associated with milder disease (group 2). Results. A high phenotypic variability was found among the patients carrying the G85E mutation. This high variability was found among patients carrying the same genotype and among siblings. All the studied chromosomes carrying the G85E mutation had the 7T variant in the polythymidine tract at the branch/acceptor site in intron 8. Of the G85E patients, 25% had pancreatic sufficiency and none had meconium ileus, compared with 0% and 32%, respectively, of patients from group 1, and 80% and 0%, respectively, from group 2. Two patients carrying the G85E mutation had sweat chloride levels <60 mmol/L whereas all the others had typically elevated levels >80 mmol/L. Compared with group 2, patients carrying the G85E mutation were diagnosed at an earlier age and had higher sweat chloride levels, with mean values similar to group 1 but significantly more variable. Forced expiratory volume in 1 second (FEV1) was similar in the three groups, with no differences in the slope or in age-adjusted mean values of FEY. The levels of transcripts lacking exon 9 transcribed from the G85E allele measured in 3 patients were 55%, 49%, and 35% and their FEV1 values were 82%, 83%, and 50% predicated, respectively. Conclusions. The G85E mutation shows variable clinical presentation in all clinical parameters. This variability could be seen among patients carrying on the other chromosome the same CFTR mutation, and also among siblings. This variability is not associated with the level of exon 9 skipping. Thus, the G85E mutation cannot be classified either as a severe or as a mild mutation.
引用
收藏
页数:6
相关论文
共 50 条
  • [41] Cystic fibrosis transmembrane conductance regulator modulators for cystic fibrosis: a new dawn?
    Edmondson, Claire
    Course, Christopher William
    Doull, Iolo
    ARCHIVES OF DISEASE IN CHILDHOOD, 2021, 106 (10) : 941 - 945
  • [42] TARGETED ACTIVATION OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR
    Villamizar, O.
    Waters, S.
    Scott, T.
    Saayman, S.
    Grepo, N.
    Urak, R.
    Davis, A.
    Morris, K.
    Jaffe, A.
    PEDIATRIC PULMONOLOGY, 2019, 54 : S183 - S184
  • [43] Cystic fibrosis transmembrane conductance regulator mutations at a referral center for cystic fibrosis
    de Araujo Correia Coutinho, Cyntia Arivabeni
    de Lima Marson, Fernando Augusto
    Ribeiro, Antonio Fernando
    Ribeiro, Jose Dirceu
    Bertuzzo, Carmen Silvia
    JORNAL BRASILEIRO DE PNEUMOLOGIA, 2013, 39 (05) : 555 - 561
  • [44] Cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis: current perspectives
    Schmidt, BeLa Z.
    Haaf, Jeremy B.
    Leal, Teresinha
    Noel, Sabrina
    CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 2016, 8 : 127 - 140
  • [45] The ΔF508 mutation disrupts packing of the transmembrane segments of the cystic fibrosis transmembrane conductance regulator
    Chen, EY
    Bartlett, MC
    Loo, TW
    Clarke, DM
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (38) : 39620 - 39627
  • [46] Relating the Disease Mutation Spectrum to the Evolution of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)
    Rishishwar, Lavanya
    Varghese, Neha
    Tyagi, Eishita
    Harvey, Stephen C.
    Jordan, I. King
    McCarty, Nael A.
    PLOS ONE, 2012, 7 (08):
  • [47] Reversal of cystic fibrosis phenotype in a cultured Δ508 cystic fibrosis transmembrane conductance regulator cell line by oligonucleotide insertion
    Zamecnik, PC
    Raychowdhury, MK
    Tabatadze, DR
    Cantiello, HF
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (21) : 8150 - 8155
  • [48] Variable levels of normal RNA in different fetal organs carrying a cystic fibrosis transmembrane conductance regulator splicing mutation
    Chiba-Falek, O
    Parad, RB
    Kerem, E
    Kerem, B
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 159 (06) : 1998 - 2002
  • [49] Localization Studies of Rare Missense Mutations in Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Facilitate Interpretation of Genotype-Phenotype Relationships
    Krasnov, Kristina V.
    Tzetis, Maria
    Cheng, Jie
    Guggino, William B.
    Cutting, Garry R.
    HUMAN MUTATION, 2008, 29 (11) : 1364 - 1372
  • [50] Targeted therapy for cystic - Cystic fibrosis transmembrane conductance regulator mutation-specific pharmacologic strategies
    Rubenstein, Ronald C.
    MOLECULAR DIAGNOSIS & THERAPY, 2006, 10 (05) : 293 - 301